Live Feeds
● LIVE Updated 1h ago · 16 sources tracked

New Drugs Are Replacing Chemo for Aggressive Breast Cancer

The FDA has approved Trodelvy and Datroway as first-line treatments for triple-negative breast cancer. These antibody-drug conjugates target specific proteins to deliver chemotherapy directly to tumor cells. Both drugs reduced the risk of disease progression by about 40% compared to standard chemotherapy.

RSS Source map (16)

What changed

Gilead's Trodelvy received FDA approval for first-line triple-negative breast cancer treatment.

Live updates

  1. FDA Approves New Targeted Therapies for Aggressive Breast Cancer

    The FDA has approved Trodelvy and Datroway as first-line treatments for triple-negative breast cancer. These antibody-drug conjugates target specific proteins to deliver chemotherapy directly to tumor cells. Both drugs reduced the risk of disease progression by about 40% compared to standard chemotherapy.

    What's confirmed:

    • The FDA approved Trodelvy for first-line triple-negative breast cancer.
    • Trodelvy can be used alone or in combination with Keytruda for first-line triple-negative breast cancer.
    • Datroway, developed by AstraZeneca and Daiichi Sankyo, was approved for a similar group of patients in May.
    • Trodelvy and Datroway reduced the risk of disease progression by about 40% compared with standard chemotherapy.
    • Both Trodelvy and Datroway are antibody-drug conjugates that target proteins on triple-negative tumor cells.
    • The FDA approved IBRANCE in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for maintenance treatment of adult patients with HR+ and HER2+ locally advanced or metastatic breast cancer.

    Still unconfirmed:

    • European regulators are expected to provide a verdict on Trodelvy's new indication later this year.
    • Upward of 48,000 Americans were diagnosed with triple-negative breast cancer last year.
    confidence 100%